Background
==========

Gene selection and cancer prediction with microarray data have been studied extensively in recent years. Most earlier studies concentrated on identifying a small number of discriminatory genes with different statistical and machine learning methods \[[@B1]-[@B3]\]. Many statistical learning techniques such as support vector machines \[[@B4]\], the relevance vector machines (RVM) \[[@B5],[@B6]\], LASSO \[[@B7]-[@B9]\], and sparse logistic regression \[[@B10]-[@B12]\] have been applied to this problem. There are two common goals for such algorithms: The first is to distinguish cancer and non-cancer patients with the highest possible accuracy. The second is to identify a small subset of genes that are highly differentiated in different classes and to associate gene expression patterns with disease status. The genes identified with the second aim may improve our understanding of the underlying causes of the cancer. In gene selection, when genes share the same biological pathway, the correlation between them can be high \[[@B13]\], and those genes form a group. The ideal gene selection methods eliminate the trivial genes and automatically include the whole group genes into the model once one gene among them is selected. Most importantly, almost all of the current methods are biased towards selecting those genes that display the most pronounced expression differences. Such methods select genes using purely statistical criteria (either rank score or classification accuracy) and this selection is thought to reflect their relative importance. Quite often, a certain number of genes with the smallest p-values or highest prediction accuracy are finally selected, while most biologists recognize that the magnitude of differential expression does not necessarily indicate biological significance. From the biological prospective, even a very small change in the expression of a particular gene may have dramatic physiological consequences if the protein encoded by this gene plays a catalytic role in a specific cell function \[[@B14]\]. Many other downstream genes may amplify the signal produced by this truly interesting gene, thereby increasing their chance of being selected by current gene selection methods. For a regulatory gene, however, the chance of being selected by such methods may diminish as one keeps hunting for downstream genes that tend to show much bigger changes in their expression. As a result, the initial list of candidate genes may be enriched with many effector genes that do little to elucidate more fundamental mechanisms of biological processes. Therefore we have to deal with two important problems in gene selection: (1) how to take into account the gene-gene correlations and (2) how to hunt the upstream regulatory genes. The characteristic of the regulatory genes is that their gene expression changes may be low, but they are highly correlated with the downstream highly expressed genes. Although there is ongoing research to incorporate prior biological knowledge, such as partially known pathways in gene selection \[[@B15]\], to the best of our knowledge, there is no efficient method to hunt the upstream regulatory genes in gene selection and pathway discovery. There is, therefore, a pressing need for new algorithms to be developed.

In this paper, we propose a substantial improvement to the sparse logistic regression (SparseLOGREG) approach \[[@B12]\]. The SparseLOGREG algorithm employs a *L*~*p*~norm regularization \[[@B16]\], which is equivalent to super Laplace prior over the model parameters. Both the generalization ability of the model and the sparsity achieved are critically dependent on the value of a regularized parameter, which has to be carefully tuned to the best performance. This best parameter can only be found through cross-validation and computationally intensive search. In this paper, the regularization parameter, however, will be integrated out analytically using a new prior that is similar to the uninformative Jeffery\'s prior \[[@B11]\]. The resulting algorithm (BLpLog) has the comparable performance with the original algorithm but is much faster, as there is no longer a need for parameter optimization. The goal of the current study is to develop a computationally affordable and well-behaved estimating approach, which can effectively identify cancer related genes and pathways. We propose an integrated method that first identifies a small subset of cancer related genes utilizing the *L*~*p*~regularized Bayesian logistic regression (BLpLog), and then define a novel similarity measure to identify the regularized genes that are highly correlated with each gene in the subset. Finally, we annotate the regularized genes and identify the cancer related pathways using DAVID.

Results and discussion
======================

In this section, we evaluate the performance of proposed *L*~*p*~penalized Bayesian logistic regression (BLpLog) methods and the integrated algorithm using several microarry data. We compare proposed method with SparseLOGREG \[[@B12]\] and BLogReg \[[@B11]\].

SparseLOGREG includes a regularization parameter, controlling the complexity of the model and the sparsity of the model parameters, which must be chosen by the user or alternatively optimized in an additional model selection stage. Therefore, the value of this parameter is found via a (computationally expensive) maximization of the cross-validation estimate of the area under the ROC curve (AUC). However, we cannot use the same cross-validation estimate for both model selection and performance evaluation as this would introduce a strong selection bias in favor of the existing sparse SparseLOGREG model. A nested cross-validation procedure is therefore used instead. 10-fold cross validation is used for performance evaluation in the \'outer loop\' of the procedure, in each iteration of which model selection is performed individually for each classifier based on a separate leave-one-out cross-validation procedure using the training data only. Because of the small sample size and high dimensional genes, leave-one-out cross validation in the \'inner loop\' likely provide a reliable performance measure for model selection. Even though this nested cross-validation is computationally expensive, it provides an almost unbiased assessment of generalization performance as well as a sensible automatic method of setting the value of the regularization parameter. We do not need model selection with both BLpLog and BLogReg, only 10-fold cross validation is used for performance evaluation. Finally, we find the highly correlated upstream genes with proposed correlation measure and identify the related pathways using DAVID.

Breast Cancer Data Set \[[@B17]\]
---------------------------------

98 primary breast cancers (34 from patients who developed distant metastases within 5 years, 44 from patients who continue to be disease-free after a period of at least 5 years, 18 from patients with BRCA1 germline mutations and 2 from BRCA2 carriers) have been selected from patients who were lymph node negative and under 55 years of age at diagnosis. There is a total of 24188 genes. This data set contained some missing values. Gene expression levels lacking for all patients are left out. The rest of the missing values are estimated based on the correlations between gene expressions.

We apply the proposed integrated algorithm to the data. BLpLog identifies 11 genes with the 10-cross-validation *AUC*= 0.976. These 11 genes are highly differentiated in patients with and without metastases. SparseLOGREG selects 10 highly differentiated genes with predicted *AUC*= 0.981, and BLogReg identifies 14 genes with the predicted *AUC*= 0.953. Both SparseLOGREG and BLpLog outperform BLogReg with higher AUC value and less genes. but that the difference in performance between the SparseLOGREG and BLpReg algorithms is minimal. The BLpLog algorithm is marginally more computational expensive than the BLogReg with multiple initializations. It takes 5 minutes compare 1.7 minutes with BLogReg algorithm. The SparseLOGREG algorithm is very much more expensive, owing to the need for a model selection stage to choose a good value for the regularization parameter. It takes roughly 4 hours on the same PC. Given the minimal difference in performance and substantial difference in computational expense there is little reason to prefer the SparseLOGREG over the BLpLog algorithm. We find the correlated genes for each of the 11 selected genes using the criteria \|*R*\| \> 0.9 and identify pathways that associated with those genes with DAVID. The 11 genes with BLpLog are listed in Table [1](#T1){ref-type="table"}. Each pathway is identified in such a way that the statistical significance of the pathway is the highest (p value is the smallest) in DAVID. The \'+\' and \'-\' signs in column 2 of Table [1](#T1){ref-type="table"} indicate that the selected gene is either over-expressed or down-expressed for patients with metastases. The total number of highly correlated genes with each selected gene is given in column 4. The highly correlated genes on a KEGG pathway are shown in Table [2](#T2){ref-type="table"}. Six pathways associated with 7 selected genes are identified. The correlated genes of the 4 other selected do not have a KEGG pathway associated with them. The plots of T cell receiptor signaling and MAPK signaling pathway are shown in Figure [1](#F1){ref-type="fig"} -- Figure [2](#F2){ref-type="fig"}. The over-expressed and and down-expressed genes on the pathway are shown in red and blue respectively. Each of these six pathways plays an important role in breast cancer survivals. For instance, JAK/STAT signaling pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. JAK activation stimulates cell proliferation, differentiation, cell migration and apoptosis. These cellular events are critical to hematopoiesis, immune development, mammary gland development and lactation, adipogenesis, sexually dimorphic growth and other processes. Predictably, mutations that reduce JAK/STAT pathway activity affect these processes. Conversely, mutations that constitutively activate or fail to regulate JAK signaling properly cause inflammatory disease, erythrocytosis, gigantism and different cancers. Moreover, LEUKOCYTE TRANSENDOTHELIAL MIGRATION provides relevant information about how cells interact with the endothelium and transmigrate. Transendothelial migration of cancer cells from the vasculature into tissue stroma is a final step in the metastatic cascade, prior to formation of secondary tumors. Patients who developed distant metastases in less than 5 years and those who had no distant metastases have 8 genes differentially expressed. The proposed integrated algorithm provides information not only about the set of genes involved on these pathways, but also about how genes interact and regulate each other. In this manuscript, we will only discuss both T CELL RECEPTOR SIGNALING PATHWAY and MAPK SIGNALING PATHWAY in more detail. Other pathways can be analyzed in a similar fashion.

###### 

BLpLog selected genes and the number of correlated

  Gene ID          Gene Name      Gene Description                             \# of Corr. Genes.
  ---------------- -------------- -------------------------------------------- --------------------
  Contig27800_RC   SFTPD (+)      surfactant, pulmonary associated protein D   213
  NM_000909        STXBP1 (-)     syntaxin binding protein 1                   411
  NM_003147        (-)            ESTs                                         229
  Contig23399_RC   (-)            ESTs                                         227
  Contig38438_RC   (-)            ESTs                                         327
  NM_003882        (-)            ESTs                                         110
  AF221520         LOC51241 (+)   hypothetical protein                         274
  AL080059         TCP1 (+)       t-complex 1                                  169
  U79298           ACTR2 (-)      ARP2 homolog                                 46
  NM_001197        FLJ10375 (-)   hypothetical protein FLJ10375                10
  NM_000599        ZNF83 (+)      hypothetical protein FLJ11015                30

###### 

Highly correlated genes and KEGG pathway

  Genes              Gene Description                                                                Pathway
  ------------------ ------------------------------------------------------------------------------- --------------------------------------
  **STXBP1**         **NM_000909**                                                                   
                                                                                                     
  CNTFR              ciliary neurotrophic factor receptor                                            JAK-STAT SIGNALING PATHWAY
  PRL                prolactin                                                                       
  SOCS3              suppressor of cytokine signaling 3                                              
  EPOR               erythropoietin receptor                                                         
  JAK2               janus kinase 2                                                                  
  CBL                cas-br-m (murine) ecotropic retroviral transforming sequence                    
  IL5RA              interleukin 5 receptor, alpha                                                   
                                                                                                     
  **ESTs**           **NM_003147**                                                                   
                                                                                                     
  SEMA3E             sema domain, immunoglobulin domain, short basic domain, (semaphorin) 3e         AXON GUIDANCE
  RASA1              ras p21 protein activator (gtpase activating protein) 1                         
  SLIT3              slit homolog 3 (drosophila)                                                     
  SRGAP3             slit-robo rho gtpase activating protein 3                                       
  EFNA5              ephrin-a5                                                                       
                                                                                                     
  **ESTs**           **Contig38438**                                                                 
                                                                                                     
  CLDN14             claudin 14                                                                      LEUKOCYTE TRANSENDOTHELIAL MIGRATION
  MAPK13             mitogen-activated protein kinase 13                                             
  CLDN4              claudin 4                                                                       
  RAP1B              member of ras oncogene family                                                   
  PTK2B              protein tyrosine kinase 2 beta                                                  
  CDC42              cell division cycle 42                                                          
  MYL6               myosin, light polypeptide 6, smooth muscle and non-muscle                       
  VCL                vinculin                                                                        
                                                                                                     
  **ESTs + ACTR2**   **NM_003882 + U79298**                                                          
                                                                                                     
  STMN1              stathmin 1/oncoprotein 18                                                       MAPK SIGNALING PATHWAY
  MAPK13             mitogen-activated protein kinase 13                                             
  MAP2K3             mitogen-activated protein kinase kinase 3                                       
  NFATC4             nuclear factor of activated t-cells, cytoplasmic, calcineurin-dependent 4       
  CACNA1H            calcium channel, voltage-dependent, alpha 1 h subunit                           
  ARRB2              arrestin, beta 2                                                                
  FGFR3              fibroblast growth factor receptor 3                                             
  ELK4               elk4, ets-domain protein                                                        
  IKBKE              inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase epsilon   
                                                                                                     
  **LOC51241**       **AF221520**                                                                    
                                                                                                     
  VAV2               vav 2 oncogene                                                                  T CELL RECEPTOR SIGNALING PATHWAY
  IL2                interleukin 2                                                                   
  CHUK               conserved helix-loop-helix ubiquitous kinase                                    
  MALT1              mucosa associated lymphoid tissue lymphoma translocation gene 1                 
  CBL                cas-br-m (murine) ecotropic retroviral transforming sequence                    
                                                                                                     
  **TCP1**           **AL080059**                                                                    
                                                                                                     
  COX10              cox10 homolog, cytochrome c oxidase assembly protein                            OXIDATIVE PHOSPHORYLATION
  ATP6V0A2           atpase, h+ transporting, lysosomal v0 subunit a2                                
  COX4I1             cytochrome c oxidase subunit iv isoform 1                                       
  COX6B1             cytochrome c oxidase subunit vib polypeptide 1 (ubiquitous)                     

![**T Cell Receiptor Signaling Pathway**. T-cell receipt signaling pathway and the associated genes identified with the integrated algorithm. The over-expressed and down-expressed genes on the pathway are shown in red and blue respectively.](1471-2105-9-412-1){#F1}

![**MAPK Signaling Pathway**. MAPK signaling pathway and the associated genes. The over-expressed and down-expressed genes on the pathway are shown in red and blue respectively.](1471-2105-9-412-2){#F2}

T Cell Receptor (TCR) Signaling (Figure [1](#F1){ref-type="fig"}) induces activation of multiple tyrosine kinases, resulting in the phosphorylation of numerous intracellular substrates. One of the first steps in the generation of the immune response is the recognition by T lymphocytes of peptide fragments (antigens) derived from foreign pathogens that are presented on the surface of antigen presenting cells (APC). This event is mediated by the T cell receptor (TCR), which transduces these extracellular signals by initiating a wide array of intracellular signaling pathways. This signaling pathway is one of the identified targets for breast cancer drug development. We identified 5 genes on the pathway: CBL, VAV, MALT1, CHUK (IKK*α*), and IL-2. VAV2, MALT1, and CHUK(IKK*α*) are also on the B-cell receiptor signal pathway. Among them, only gene VAV2 is down-expressed in patients with distant metastases in less than 5 years. The other 4 genes are up-expressed. VAV2 is an oncogene and plays a critical role in hematopoietic signal transduction. The down-expressed Vav2 has been implicated in breast cancer metastasis and may prove to be very important in the aberrant activation of Rho GTPases during the metastatic cascade. The other 4 over-expressed genes are also very important for breast and other cancers and were well studied in the literature. For example, the CBL oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation. MALT1, CHUK, and IL-2 are also important oncogene identified. These 3 genes have the causal relations as shown in Figure [1](#F1){ref-type="fig"}. MALT1 is defined as the mucosa associated lymphoid tissue lymphoma translocation gene 1. The over-expressed MALT2 in patients with distant metastasis causes the over-expressed CHUK, and then the over-expressed IL-2. Therefore, MALT1 is essential for T cell activation, proliferation, and IL-2 production. If MALT1 is not present, both CHUK and IL-2 will shut-off.

The Mitogen-Activated Protein Kinase (MAPK) signaling pathway (Figure [2](#F2){ref-type="fig"}) transduces a large variety of external signals, leading to a wide range of cellular responses, including growth, differentiation, inflammation and apoptosis. The MAPK signaling pathway has been linked to being responsible for the malignant phenotype, including increased proliferation, defects in apoptosis, invasiveness and ability to induce neovascularization. Consequently, different therapies towards inhibiting the pathway are under development. Nine genes were identified on the pathway. Patients with metastases in less than 5 years are over-expressed in 8 genes and down-expressed in one gene (Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

There are several causal relations among them. For instance, EGFR belong to the family of epidermal growth factor receptors and has been proven to play major roles in different histological types of breast cancer. The over-expressed EGFR in patients with metastases may be responsible for the up-expressed STMN1 and the down-expressed ELK4 (Sap1a). ELK4 is a downstream gene on the MAPK pathway. Moreover, the the over-expressed MAP2K3 (MKK3) causes the over-expressed MAPK12(P38), and then causes the down-expressed ELK4 (Sap1a). The systematic review of the interactions among the correlated genes on a specific pathway provides us more information about how various genes interact with each other and which gene plays a catalytic role and is more important. EGFR3 is certainly a more important upstream gene and mutations that lead to EGFR over-expression (or overactivity) have been associated with a number of cancers. The over-expressed EGFR in patients with metastases has led to the development of anticancer therapeutics directed against EGFR.

Hepatocellular carcinoma data set \[[@B18]\]
--------------------------------------------

mRNA expression profiles in tissue specimens from 60 hepatocellular carcinoma tissues of which 20 suffer from early intrahepatic recurrence and 40 do not. The number of gene expression levels is 7129. Since hepatocellular carcinoma has a poor prognosis because of the high intrahepatic recurrence rate, the original goal is to predict early intrahepatic recurrence or non-recurrence. With the proposed integrated algorithm, we can identify not only the highly differentiated genes but also the related pathways.

BLpLog identifies 8 highly differentiated genes with the test *AUC*= 0.93 with the computational time of 3.2 minutes. BLogReg selects 13 genes with the predicted *AUC*= 0.90 and computational time of 1.6 minutes. SparseLOGREG identifies 10 genes with the predicted *AUC*= 0.936 and computational time of 127 minutes (2 hours). The selected genes with different methods are not completely the same but highly correlated. Again with the minimal difference in performance and big differences in computational time between BLpLog and SparseLOGREG, obviously BLpLog is preferred. The highly correlated genes and corresponding pathways are selected with the integrated algorithm. Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"} are the computational results. Seven pathways was identified from the data. The plots of Antigen Processing and Presentation and Axon Guidance pathways are shown in Figure [3](#F3){ref-type="fig"} -- Figure [4](#F4){ref-type="fig"}. All eight pathways identified are important in hepatocellular carcinoma and other cancers. For example, PURINE METABOLISM pathway is one of the metabolism pathways involved in nucleotide synthesis and degradation, amino acid catabolism, non-essential amino acid synthesis and the urea cycle. Understanding the mechanism involved in metabolic regulation has important implications in both biotechnology and medicine. It is estimated that at least a third of all serious health problems are caused by metabolic disorders. Analyzing differentiated expressed genes on the pathway may provide some insight on the early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Other pathways such as CYTOKINE-CYTOKINE RECEPTOR INTERACTION, NEUROACTIVE LIGAND-RECEPTOR INTERACTION, MAPK SIGNALING PATHWAY, and GAP JUNCTION are all hepatocellular carcinoma related. We will discuss the two pathways ANTIGEN PROCESSING AND PRESENTATION and AXON GUIDANCE in more details.

###### 

BLpLog selected genes and the number of correlated

  A3y ID          Gene Description                                                                               \# of Corr. Genes
  --------------- ---------------------------------------------------------------------------------------------- -------------------
  D26600_at (+)   Human mRNA for proteasome subunit HsN3                                                         133
  M16973_at (-)   Human complement protein C8 beta subunit mRNA                                                  124
  M63573_at (+)   Human secreted cyclophilin-like protein (SCYLP) mRNA                                           103
  U79294_at(-)    Human clone 23748 mRNA, complete cds                                                           102
  U94586_at(+)    ubiquinone oxidoreductase MLRQ subunit mRNA                                                    122
  X00274_at(-)    Human gene for HLA-DR alpha heavy chain a class II antigen (immune response gene) of the MHC   92
  X59798_at (+)   Human PRAD1 mRNA for cyclin                                                                    107
  X69141_at (+)   H. sapiens mRNA for squalene synthase                                                          99

###### 

KEGG pathway and the highly correlated genes

  Genes                         Gene Description                                                                                                      Pathway
  ----------------------------- --------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  **D26600_at and X59798_at**                                                                                                                         
                                                                                                                                                      
  X06562_at                     growth hormone receptor                                                                                               CYTOKINE-CYTOKINE RECEPTOR
  X95095_at                     platelet-derived growth factor receptor, alpha polypeptide                                                            
  M12783_at                     platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog)                       
  M20137_at                     interleukin 3 (colony-stimulating factor, multiple)                                                                   
  L36033_at                     chemokine (c-x-c motif) ligand 12 (stromal cell-derived factor 1)                                                     
  V00532_rna1_f\_at             interferon, alpha 17                                                                                                  
  U11877_at                     interleukin 8 receptor, beta                                                                                          
  V00542_f\_at                  interferon, alpha 14                                                                                                  
  D49410_at                     interleukin 3 receptor, alpha (low affinity)                                                                          
  X04688_at                     interleukin 5 (colony-stimulating factor, eosinophil)                                                                 
  X02958_at                     interferon, alpha 6                                                                                                   
  X00695_s\_at                  interleukin 2                                                                                                         
  U02687_at                     fms-related tyrosine kinase 3                                                                                         
  M83554_at                     tumor necrosis factor receptor superfamily, member 8                                                                  
  D43767_at                     chemokine (c-c motif) ligand 17                                                                                       
  X02958_at                     interferon, alpha 1                                                                                                   
  U83326_s\_at                  chemokine (c-c motif) receptor 5                                                                                      
  X02958_at                     interferon, alpha 5                                                                                                   
                                                                                                                                                      
  **M16973_at**                                                                                                                                       
                                                                                                                                                      
  M86868_at                     gamma-aminobutyric acid (gaba) receptor, rho 2                                                                        NEUROACTIVE LIGAND RECEPTOR INTERACTION
  U49395_at                     purinergic receptor p2x, ligand-gated ion channel, 5                                                                  
  U68133_at                     cannabinoid receptor 1 (brain)                                                                                        
  K01911_at                     neuropeptide y                                                                                                        
  M31210_at                     endothelial di3erentiation, sphingolipid g-protein-coupled receptor, 1                                                
  D85376_at                     thyrotropin-releasing hormone receptor                                                                                
  M18185_at                     gastric inhibitory polypeptide                                                                                        
  L27080_at                     melanocortin 5 receptor                                                                                               
  X82068_at                     glutamate receptor, ionotrophic, ampa 3                                                                               
                                                                                                                                                      
  **M63573_at**                                                                                                                                       
                                                                                                                                                      
  U61538_at                     calcium binding protein p22                                                                                           AXON GUIDANCE
  M14949_at                     related ras viral (r-ras) oncogene homolog                                                                            
  L36033_at                     chemokine (c-x-c motif) ligand 12 (stromal cell-derived factor 1)                                                     
  X17576_at                     nck adaptor protein 1                                                                                                 
  M17219_at                     guanine nucleotide binding protein (g protein), alpha inhibiting activity polypeptide 1                               
  L41939_at                     eph receptor b2                                                                                                       
  X76132_at                     deleted in colorectal carcinoma                                                                                       
                                                                                                                                                      
  **U79294**                                                                                                                                          
                                                                                                                                                      
  M92432_at                     guanylate cyclase 2d, membrane (retina-specific)                                                                      PURINE METABOLISM
  U40370_at                     phosphodiesterase 1a, calmodulin-dependent                                                                            
  Y00971_at                     phosphoribosyl pyrophosphate synthetase 1                                                                             
  X59618_at                     ribonucleotide reductase m2 polypeptide                                                                               
  Z46632_at                     phosphodiesterase 4c, camp-specific                                                                                   
                                                                                                                                                      
  **U94586_at**                                                                                                                                       
                                                                                                                                                      
  HT3620_s\_at                  fibroblast growth factor receptor 2                                                                                   MAPK SIGNALING PATHWAY
  M76559_at                     calcium channel, voltage-dependent, alpha 2/delta subunit 1                                                           
  M38449_s\_at                  transforming growth factor, beta 1                                                                                    
  U66464_at                     mitogen-activated protein kinase kinase kinase kinase 1                                                               
  U71087_at                     mitogen-activated protein kinase kinase 5                                                                             
  U13021_s\_at                  caspase 2, apoptosis-related cysteine peptidase (neural precursor cell expressed, developmentally down-regulated 2)   
  D12625_at                     neurofibromin 1                                                                                                       
  S78187_at                     cell division cycle 25b                                                                                               
                                                                                                                                                      
  **X00274_at**                                                                                                                                       
                                                                                                                                                      
  M33600_f\_at                  major histocompatibility complex, class ii, dr beta 1                                                                 ANTIGEN PROCESSING AND PRESENTATION
  X00274_at                     major histocompatibility complex, class ii, dr alpha                                                                  
  X03100_cds2                   major histocompatibility complex, class ii, dp alpha 1                                                                
  M13560_s\_at                  cd74 antigen (invariant polypeptide of major histocompatibility complex, class ii antigen-associated)                 
  D45248_at                     proteasome (prosome, macropain) activator subunit 2                                                                   
  J00105_s\_at                  beta-2-microglobulin                                                                                                  
  M17236_s\_at                  major histocompatibility complex, class ii, dq alpha 1                                                                
  HG658-HT658_f\_at             major histocompatibility complex, class i, b                                                                          
                                                                                                                                                      
  **X69141_at**                                                                                                                                       
                                                                                                                                                      
  Y07512_at                     protein kinase, cgmp-dependent, type i                                                                                GAP JUNCTION
  M18255_cds2_s\_at             protein kinase c, beta 1                                                                                              
  Z11695_at                     mitogen-activated protein kinase 1                                                                                    
  X80763_s\_at                  5-hydroxytryptamine (serotonin) receptor 2c                                                                           

![**Antigen Processing and Presentation**. Antigen processing and presentation pathway and the associated genes. The over-expressed and down-expressed genes on the pathway are shown in red and blue respectively.](1471-2105-9-412-3){#F3}

![**Axon Guidance**. Axon guidance pathway and the associated genes. The over-expressed and down-expressed genes on the pathway are shown in red and blue respectively.](1471-2105-9-412-4){#F4}

ANTIGEN PROCESSING AND PRESENTATION are processes that occur within a cell that result in fragmentation (proteolysis) of proteins, association of the fragments with MHC molecules, and expression of the peptide-MHC molecules at the cell surface where they can be recognized by the T cell receptor on a T cell. However, the path leading to the association of protein fragments with MHC molecules differs for class I and class II MHC. MHC class I molecules present degradation products derived from intracellular (endogenous) proteins in the cytosol. MHC class II molecules present fragments derived from extracellular (exogenous) proteins that are located in an intracellular compartment. Both MHC class I and class II pathways play an important role in anti-tumor immune responses. Patients with early intrahepatic recurrence of hepatocellular carcinoma (HCC) have the down-expressed expression both on MHC I and II pathways. It is generally acknowledged that tumors usually escape from host immune surveillance by dysfunction or defect of MHC I and MHC II presentation pathways with the down-expressed genes. Therefore, the down-expressed genes on the pathway may be one of the critical reasons for early intrahepatic recurrence. The causal relations among genes can also be identified in Figure [3](#F3){ref-type="fig"}. The down-expressed MHCI gene may cause the down-expressed *β*2m and the down-expressed MHCII and/or LI gene may cause the down-expressed SLIP and the down-expressed SLIP may cause the down-expressed CLIP. These causal relations may provide some implications on developing medicines against hepatocellular carcinoma. AXON GUIDANCE (also called axon pathfinding) is a subfield of neural development concerning the process by which neurons send out axons to reach the correct targets. Many axon guidance molecules may regulate cell migration and apoptosis in normal and tumorigenic tissues. Recent studies have shown that they are widely expressed outside the nervous system and that they may play important roles in HCC. Genes and their interactions are shown in Figure [4](#F4){ref-type="fig"}. For example, mutations in the ras oncogenes have been linked to many different cancers. Ras gene is over-expressed for HCC patients with early intrahepatic recurrence. The causal relations and gene-gene interactions are also shown in Figure [4](#F4){ref-type="fig"}. For instance, the down-expressed EpbB gene in patients with intrahepatic recurrence may cause the over-expressed ras gene through MAPK signaling pathway. The over-expressed DCC gene in patients with intrahepatic recurrence may cause the down-expressed Nck1 and over-expressed CALN, and so on. These gene-gene interactions may have prognostic implications for HCC.

High-grade glioma data set \[[@B19]\]
-------------------------------------

50 high-grade glioma samples were carefully selected, 28 glioblastomas and 22 anaplastic oligodendrogliomas, all were primary tumors sampled before therapy. The classic subset of tumors were cases diagnosed similarly by all examining pathologists, and each case resembled typical depictions in standard textbooks. A total of 21 classic tumors was selected, and the remaining 29 samples were considered nonclassic tumors, lesions for which diagnosis might be controversial. Affymetrix arrays are used to determine the expression of over 12000 genes. The original goal is to separate the glioblastomas from the anaplastic oligodendrogliomas, which allows appropriate therapeutic decisions and prognostic estimation. The number of gene expression levels is 12625. Our goal is to identify genes and corresponding pathways associated with malignant gliomas.

BLpLog has identified 14 genes that are highly differentiated expressed in glioblastomas and anaplastic oligodendrogliomas (predicted AUC = 0.98). Eight pathways and associated correlated genes are identified with the integrated algorithm. The computational results are given in Table [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}. The plots of FOCAL ADHESION and RIBOSOME pathways are shown in Figure [5](#F5){ref-type="fig"} -- Figure [6](#F6){ref-type="fig"}. The eight identified pathways are important in malignant gliomas and other diseases. For instance, COMPLEMENT AND COAGULATION CASCADES are composed of serine proteases that are activated through partial cleavage by an upstream enzyme. The elements of these cascades share several common structural characteristics, including a highly conserved catalytic site composed of Ser, His and Asp. The common principle underlying the organization of these systems is that proteases exist as inactive zymogens and are subsequently activated by upstream, active proteases. The initial activation might occur as a result of contact with a non-enzymatic ligand or cleavage by another protease. Understanding the interplay between complement and coagulation has fundamental clinical implications in the context of cancers with an inflammatory pathogenesis. Migration and invasion are important prerequisites for the infiltrative and destructive growth patterns of malignant gliomas. The glioma cell invasiveness depends on proteases of the coagulation and complement cascades. Another pathway, GLUTATHIONE METABOLISM, works through the operation of a group of enzymes called glutathione S-transferases (GST). Glutathione (GSH) plays a critical role in cellular mechanisms that result in cell death. The high glutathione levels may cause resistance to chemotherapy drugs. One interesting study by researchers in Texas showed that your chances of surviving a type of brain cancer, called primary malignant glioma, could depend on the type of glutathione-s-transferase (GST) gene you were born with. Therefore, it is possible to target glutathione metabolism in the prevention and treatment of malignant gliomas. Here we discuss the FOCAL ADHESION and RIBOSOME pathways in more details.

###### 

BLpLog selected genes and the number of correlated

  AFFY ID           Gene Description                                                      \# of corr Genes
  ----------------- --------------------------------------------------------------------- ------------------
  yj12d03.s1 (+)    Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE 148517 3          189
  245_at(-)         HUMLNHR Human lymph node homing receptor mRNA, complete cds           149
  32140_at (-)      H. sapiens mRNA for mosaic protein LR11                               140
  33117_r\_at (-)   oq25a04.s1 Homo sapiens cDNA, 3 end                                   139
  34279_at (+)      Homo sapiens mRNA                                                     154
  34645_at (-)      Human Hums3 mRNA for 40S ribosomal protein s3                         76
  35628_at (-)      Homo sapiens lamin B receptor homolog TM7SF2 mRNA, complete cds       191
  36452_at (+)      Homo sapiens mRNA for KIAA1029 protein, complete cds                  165
  37591_at (-)      Human uncoupling protein homolog (UCPH) mRNA, complete cds            228
  37915_at (+)      cDNA DKFZp434H071 (from clone DKFZp434H071)                           290
  38079_at (+)      cDNA DKFZp586B0918 (from clone DKFZp586B0918)                         213
  40419_at (-)      H. sapiens epb72 gene exon 1                                          204
  41213_at (+)      H. sapiens mRNA for proliferation associated gene (pag)               158
  675_at (-)        HUM927A Human interferon-inducible protein 9--27 mRNA, complete cds   210

###### 

KEGG pathway and the highly correlated genes

  Genes                                Gene Description                                                              Pathway
  ------------------------------------ ----------------------------------------------------------------------------- ---------------------------------------------
  **yj12d03.s1 and 35628)\_at**                                                                                      
                                                                                                                     
  33520_at                             coagulation factor vii (serum prothrombin conversion accelerator)             COMPLEMENT AND COAGULATION CASCADES
  31591_s\_at                          complement factor h                                                           
  37550_at                             coagulation factor viii, procoagulant component (hemophilia a)                
  41701_at                             complement component 6                                                        
  37175_at                             serpin peptidase inhibitor, clade c (antithrombin), member 1                  
                                                                                                                     
  **245_at and 36452_at**                                                                                            
                                                                                                                     
  2023_g\_at                           v-akt murine thymoma viral oncogene homolog 2                                 FOCAL ADHESION
  40438_at                             protein phosphatase 1, regulatory (inhibitor) subunit 12a                     
  1560_g\_at                           p21 (cdkn1a)-activated kinase 2                                               
  40162_s\_at                          cartilage oligomeric matrix protein                                           
  33994_g\_at                          myosin, light polypeptide 6, alkali, smooth muscle and non-muscle             
  33627_at                             phosphoinositide-3-kinase, catalytic, delta polypeptide                       
  659_g\_at                            thrombospondin 2                                                              
  32029_at                             3-phosphoinositide dependent protein kinase-1                                 
  39765_at                             talin 2                                                                       
  41350_at                             collagen, type vi, alpha 1                                                    
  954_s\_at                            protein phosphatase 1, catalytic subunit, alpha isoform                       
  38812_at                             laminin, beta 2 (laminin s)                                                   
  37909_at                             laminin, alpha 3                                                              
  34724_at                             glucocorticoid receptor dna binding factor 1                                  
  1557_at                              p21/cdc42/rac1-activated kinase 1                                             
                                                                                                                     
  **32140_at**                                                                                                       
                                                                                                                     
  33134_at                             adenylate cyclase 3                                                           GAP JUNCTION
  429_f\_at                            tubulin, beta 2b                                                              
  429_f\_at                            tubulin, beta 2a                                                              
  1000_at                              mitogen-activated protein kinase 3                                            
  429_f\_at                            tubulin, beta 4                                                               
                                                                                                                     
  **33117_r\_at and 34645_at**                                                                                       
                                                                                                                     
  32440_at                             ribosomal protein l17                                                         RIBOSOME
  32337_at                             ribosomal protein l21                                                         
  31907_at                             ribosomal protein l14                                                         
  36333_at                             ribosomal protein l7                                                          
  31952_at                             ribosomal protein l6                                                          
  32437_at                             ribosomal protein s5                                                          
  35119_at                             similar to ribosomal protein l13a                                             
  31957_r\_at                          ribosomal protein, large, p1                                                  
  34645_at                             ribosomal protein s3                                                          
  31538_at                             ribosomal protein, large, p0                                                  
  31722_at                             ribosomal protein l3                                                          
  31545_at                             ribosomal protein s18                                                         
  32466_at                             ribosomal protein l41                                                         
  34593_g\_at                          ribosomal protein s17                                                         
  35119_at                             ribosomal protein l13a                                                        
  32394_s\_at                          ribosomal protein l23                                                         
  41178_at                             ribosomal protein l11                                                         
  33117_r\_at                          ribosomal protein s12                                                         
  36786_at                             ribosomal protein l10a                                                        
                                                                                                                     
  **37591_at**                                                                                                       
                                                                                                                     
  37956_at                             aldehyde dehydrogenase 3 family, member b2                                    METABOLISM OF XENOBIOTICS BY CYTOCHROME P45
  375_at                               glutathione s-transferase theta 1                                             
  37707_i\_at                          alcohol dehydrogenase 5 (class iii), chi polypeptide                          
  33396_at                             glutathione s-transferase pi                                                  
  1080_s\_at                           cytochrome p450, family 1, subfamily a, polypeptide 2                         
                                                                                                                     
  **37915_at, 38079_at, and 675_at**                                                                                 
                                                                                                                     
  36294_at                             serine/threonine kinase 4                                                     MAPK SIGNALING PATHWAY
  39647_s\_at                          calcium channel, voltage-dependent, beta 2 subunit                            
  38743_f\_at                          v-raf-1 murine leukemia viral oncogene homolog 1                              
  39932_at                             dual specificity phosphatase 7                                                
  36935_at                             ras p21 protein activator (gtpase activating protein) 1                       
  1292_at                              dual specificity phosphatase 2                                                
  34006_s\_at                          mitogen-activated protein kinase 8                                            
  41432_at                             ribosomal protein s6 kinase, 90 kda, polypeptide 5                            
  971_s\_at                            transforming growth factor, beta 2                                            
  438_at                               protein kinase, camp-dependent, catalytic, alpha                              
  1239_s\_at                           caspase 2, apoptosis-related cysteine peptidase                               
  38272_at                             dual specificity phosphatase 14                                               
  41226_at                             dual specificity phosphatase 3                                                
  37644_s\_at                          fas (tnf receptor superfamily, member 6)                                      
  113_i\_at                            microtubule-associated protein tau                                            
  249_at                               nuclear factor of activated t-cells, cytoplasmic, calcineurin-dependent 4     
  1788_s\_at                           dual specificity phosphatase 4                                                
  31993_f\_at                          calcium channel, voltage-dependent, beta 2 subunit                            
  38079_at                             guanine nucleotide binding protein (g protein), gamma 12                      
  1378_g\_at                           nuclear factor of kappa light polypeptide gene enhancer in b-cells 1 (p105)   
  34521_at                             mitogen-activated protein kinase kinase kinase 13                             
  37575_at                             activating transcription factor 2                                             
  1327_s\_at                           mitogen-activated protein kinase kinase kinase 5                              
  40030_at                             protein kinase, y-linked                                                      
  36168_at                             fibroblast growth factor receptor 1                                           
  36004_at                             inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase gamma   
  32304_at                             protein kinase c, alpha                                                       
  39822_s\_at                          growth arrest and dna-damage-inducible, beta                                  
  31618_at                             tumor protein p53 (li-fraumeni syndrome)                                      
  39672_at                             protein tyrosine phosphatase, non-receptor type 7                             
  32749_s\_at                          filamin a, alpha (actin binding protein 280)                                  
                                                                                                                     
  **40419_at**                                                                                                       
                                                                                                                     
  40273_at                             sphingosine kinase 2                                                          GLYCOSPHINGOLIPID METABOLISM
  41568_at                             arylsulfatase d                                                               
  38818_at                             serine palmitoyltransferase, long chain base subunit 1                        
  40214_at                             udp-glucose ceramide glucosyltransferase                                      
                                                                                                                     
  **41213_at**                                                                                                       
                                                                                                                     
  556_s\_at                            glutathione s-transferase m4                                                  GLUTATHIONE METABOLISM
  556_s\_at                            glutathione s-transferase m1                                                  
  556_s\_at                            glutathione s-transferase m2 (muscle)                                         
  32893_s\_at                          gamma-glutamyltransferase 2                                                   
  32893_s\_at                          gamma-glutamyltransferase 1                                                   
  32893_s\_at                          gamma-glutamyltransferase-like 4                                              

![**FOCAL ADHESION**. FOCAL ADHESION pathway and the associated genes. The over-expressed and down-expressed genes on the pathway are shown in red and blue respectively.](1471-2105-9-412-5){#F5}

![**RIBOSOME**. Ribosome pathway and the associated genes. The over-expressed and down-expressed genes on the pathway are shown in red and blue respectively.](1471-2105-9-412-6){#F6}

FOCAL ADHESIONS are large, dynamic protein complexes through which the cytoskeleton of a cell connects to the extracellular matrix, or ECM. They can be considered as sub-cellular macromolecules that mediate the regulatory effects (e.g. cell anchorage) of extracellular matrix (ECM) adhesion on cell behavior. Focal adhesions kinase (FAK) contributes to glioma growth and invasion. FAK integrates signals from activated growth factor receptors and integrins to regulate cell motility, invasion, proliferation, apoptosis, and angiogenesis. It, therefore, promotes tumor growth, and a role for FAK in glioma pathogenesis is suggested by its expression and localization. FAK genes are over-expressed on the pathway for glioblastoma patients as shown in Figure [5](#F5){ref-type="fig"}. These over-expressed genes may have many potential pro-tumorigenic functions and produce chemotherapy resistance in the glioblastoma patients. The causal relations and gene-gene interactions are also shown in Figure [5](#F5){ref-type="fig"}. The over-expressed ECM gene is a causal gene that causes several other genes to be over-expressed. If ECM is not present, the entire pathway is shut off. Conversely, the expression changes of downstream genes such as MLC and PAK may not affect the pathway as much.

Ribosome biology is huge and accounts for up to 50% of transcriptional activity of cells. The RIBOSOME pathway is composed of genes that encode various proteins of the ribosomal subunits. These proteins need to interact physically with each other to form a large protein complex, the ribosome, and are thereby closely related functionally. Ribosome biogenesis and translation are regulated at multiple levels and are associated with accurate cell growth and proliferation. Several tumor suppressors and proto-oncogenes have been found either to affect the formation of the mature ribosome or to regulate the activity of proteins known as translation factors. Disruption in one or more of the steps that control protein biosynthesis has been associated with alterations in the cell cycle and regulation of cell growth. Therefore, certain tumor suppressors and proto-oncogenes might regulate malignant progression by altering the protein synthesis machinery. The protein genes on RIBOSOME pathway (Figure [6](#F6){ref-type="fig"}) are down-expressed in glioblastoma patients. These down-expressed genes may provide some insight on how to develop new drugs and cancer therapies to target the RIBOSOME pathway involved in malignant gliomas.

Conclusion
==========

We have developed a Bayesian *L*~*p*~Logistic regression (BLpLog) method, defined a novel correlation measure, and proposed an integrated algorithm for gene selection and pathway identification. We have demonstrated that the simple Bayesian approach to integrating the regularization parameter out analytically performed well on prediction. The integrated algorithm can identify cancer associated genes and KEGG pathways efficiently with the test data sets. The correlation measure we defined can be used to hunt those upstream regularized genes with low expression levels, but are strongly correlated with the downstream highly differentiated genes identified with BLpLog. Almost all of the pathways found in this manuscript cannot be identified with the traditional correlation coefficient. The identified pathways can provide information on gene-gene interactions and causal relations for genes on the pathway. The knowledge of gene-gene interaction, gene regulation, and biological pathways can be applied to understanding the mechanisms of how pathway regulations have changed in different subtypes of cancer patients.

Mining high throughput data from different aspects can help us understand the cancer biology better. Our method provided much more information than we presented. For instance, we found hundreds of correlated genes for each downstream gene identified with BLpLog. Only a small proportion of the correlated genes is on the known KEGG pathways. We did not explore the functions and causal relations of the rest of the genes. Moreover, although there may be multiple pathways for each gene, we only reported the top pathway with the highest count of genes. We will infer the gene regulatory networks with the rest of the correlated genes and explore multiple pathways in the near future. Finally, gene set enrichment analysis \[[@B20]\] is a popular tool for evaluating microarray data at the level of gene sets. It, first, utilize a statistical test to identify highly differentiated upstream genes in two classes, and then define gene sets based on prior biological knowledge. There are two drawbacks with this method: (1) it is solely based on the partially known biological knowledge and (2) it cannot guarantee the upstream regularized genes to be selected in the set. It is, therefore, of great interests to incorporate the proposed correlation measure *R*into gene enrichment analysis, so that we can make sure the upstream regularized genes in the studied gene sets. This is the work of our future research.

Methods
=======

*L*~*p*~Regularized Sparse Logistic Regression
----------------------------------------------

A general binary classification problem may be simply described as follows. Given *n*samples, *D*= {(**x**~1~, *y*~1~), \..., (**x**~*n*~, *y*~*n*~)}, where **x**~*i*~is a multidimensional input vector with dimension *d*and class label *y*~*i*~∈ {-1, 1}, find a classifier *f*(**x**) such that for any input **x**with class label y, *f*(**x**) predicts class y correctly. The logistic regression is:

$$\left. P(y = \pm 1 \middle| \mathbf{x},\mathbf{w}) = g(y\mathbf{w}^{T}\mathbf{x}) = \frac{1}{1 + \exp( - y\mathbf{w}^{T}\mathbf{x})}, \right.$$

where **w**= (*w*~1~, \..., *w*~*d*~)^*T*^are the parameters which can be estimated through maximizing the log likelihood or minimizing the negative log likelihood.

$$\left. E_{D} = - l(\mathbf{w} \middle| D) = {\sum\limits_{i = 1}^{n}{\log(1 + \exp( - y_{i}\mathbf{w}^{T}\mathbf{x}_{i})).}} \right.$$

Different prior assumptions of **w**in the maximum a-posteriori (MAP) estimation will lead to different regularization terms. The sparse parameter estimates can be achieved with *L*~*p*~regularization:

where

$$\begin{matrix}
{L_{p} = {\sum\limits_{i = 1}^{d}\left| w_{i} \right|^{p}},} & \text{where} & {0 < p \leq 1,} \\
\end{matrix}$$

where *λ*≥ 0 is a regularization parameter which must be tuned and $L_{p} = {\sum_{j = 0}^{d}\left| w_{j} \right|^{p}}$ is the regularization term.

### Bayesian Regularization

Choosing the best regularization parameter *λ*through cross-validation is time consuming. Therefore we propose a Bayesian regularization framework to integrate out the parameter following the similar methods of \[[@B11],[@B21],[@B22]\]. Minimizing E in equation (1) has the straight forward Bayesian interpretation. The posterior distribution for **w**is given by

$$\left. p(\mathbf{w} \middle| D) = \frac{\left. p(D \middle| \mathbf{w})p(\mathbf{w} \middle| \lambda) \right.}{p(D)}, \right.$$

where *p*(*D*) = ∫ *P*(*D*\|**w**)*p*(**w**\|*λ*)d**w**d*λ*is a normalization factor that ensures that the posterior integrates to 1 and is given by an integral over the parameter space. The distribution of *p*(*D*\|**w**) is defined as:

$$\left. p(D \middle| \mathbf{w}) = {\prod\limits_{i = 1}^{n}\left. p(y_{i} \middle| \mathbf{x},\mathbf{w}) = {\prod\limits_{i = 1}^{n}{\frac{1}{(1 + \exp( - y_{i}\mathbf{w}^{T}\mathbf{x})}.}} \right.} \right.$$

Let\'s $\left. E_{w_{i}} = \middle| w_{i} \right|^{p}$, and we have $L_{p} = {\sum_{i = 1}^{m}E_{w_{i}}}$, where *m*is the number of non-zero model parameters and obviously *m*≤ *d*. The prior over model parameter, **w**, can be defined as

$$\left. p(\mathbf{w} \middle| \lambda) = \frac{1}{C(\lambda)}{\prod\limits_{i = 1}^{m}{\lambda\exp( - \lambda E_{w_{i}}) = \frac{\lambda^{m}}{C(\lambda)}\exp( - \lambda L_{p})}}, \right.$$

where $C(\lambda) = {\int{\prod_{i = 1}^{m}{\exp( - \lambda L_{p})\text{d}\mathbf{w}}}}$ is a normalization constant for a given *λ*. Taking the negative logarithm of the posterior density of equation (2), we have

Therefore,

The hyperparameter *λ*can be integrated out analytically in the prior distribution *p*(**w**\|*λ*).

As *λ*is a scaler, we can assign a new prior such that *p*(*λ*) ∝ *C*(*λ*)/*λ*. Substituting equation (3), we have

$$p(\mathbf{w}) = {\prod\limits_{i = 1}^{m}{{\int_{0}^{\infty}\lambda^{m - 1}}\exp\left\{ - \lambda L_{p} \right\}\text{d}\lambda}}.$$

Using the Gamma integral ${\int_{0}^{\infty}{x^{v - 1}e^{- \mu x}\text{d}x}} = \frac{\Gamma(v)}{\mu^{v}}$, we get

$$p(\mathbf{w}) = \frac{\Gamma(m)}{L_{p}^{m}}.$$

Since $\left. p(\mathbf{w} \middle| D) = \frac{\left. P(D \middle| \mathbf{w})p(\mathbf{w}) \right.}{p(D)} \right.$, we have

Let *Q*= *E*~*D*~+ *m*log *L*~*p*~, comparing equation (4) with (5), we have

where *R*= log *p*(*D*) - log Γ(*m*) is a constant not related to **w**. Therefore, *E*and *Q*are identical up to an additive constant and minimizing *E*is equivalent to minimizing the Bayesian regularization error function *Q*.

### The BLpLog Algorithm

To find the optimal value of *Q*and **w**, we need to have the first and/or second order derivative with gradient based methods. One difficulty with *L*~*p*~is that it is not differentiable at zero and a differentiable approximation of *L*~*p*~has to be used. Differentiable approximations typically have a parameter that controls the trade-off between the smoothness of the approximation and the closeness of the non-differentiable function which is being approximated. One approximation which works for *p*≤ 1 is

$$L_{p} = {\sum\limits_{j = 0}^{d}\left. ( \middle| w_{i} \middle| {}_{2} + \gamma) \right.^{p/2}},$$

where *γ*is the smoothing parameter. With this differentiable approximation, we get the following modified error function:

$$\left. Q \approx Q_{\gamma} = E_{D} + m\log L_{p} = - l(\mathbf{w} \middle| D) + m\log({\sum\limits_{j = 0}^{d}{\left. ( \middle| w_{i} \middle| {}_{2} + \gamma) \right.^{p/2})}}. \right.$$

Note that *Q*~*γ*~→ *Q*as *γ*→ 0.

Given a small value *γ*, the gradient can be calculated as:

$$\nabla_{\mathbf{w}}Q_{\gamma} = - {\sum\limits_{i}{(1 - g(y_{i}\mathbf{w}^{T}\mathbf{x}_{i}))y_{i}\mathbf{x}_{i} + m\frac{\nabla_{\mathbf{w}}L_{p}}{L_{p}},}}$$

where

$$\nabla_{\mathbf{w}}L_{p} = \text{vec}\left\{ \frac{pw_{i}}{\left. ( \middle| w_{i} \middle| {}_{2} + \gamma) \right.^{1 - p/2}} \right\},$$

where vec{·} represents a vector whose *i*-th element is given by the expression inside the brackets. The Hessian of the objective function is:

$$H = \nabla_{\mathbf{ww}}Q_{\gamma} = {\sum\limits_{i}{g(\mathbf{w}^{T}\mathbf{x}_{i})(1 - g(\mathbf{w}^{T}\mathbf{x}_{i}))\mathbf{x}_{i}\mathbf{x}_{i}^{T}}} + m\frac{L_{p}\nabla_{\mathbf{ww}}L_{p} - {(\nabla_{\mathbf{w}}L_{p})}^{2}}{L_{p}^{2}},$$

where

$$\nabla_{\mathbf{ww}}L_{p} = \text{diag}\left\{ {\frac{p}{\left. ( \middle| w_{i} \middle| {}_{2} + \gamma) \right.^{1 - p/2}} + \frac{\left. p(p - 2) \middle| w_{i} \right|^{2}}{\left. ( \middle| w_{i} \middle| {}_{2} + \gamma) \right.^{2 - p/2}}} \right\},$$

where diag{·} is the diagonal matrix whose *i*-th diagonal element is given by the expression inside the brackets. Let

we have the matrix form of H:

$$H = XAX^{T} + m\frac{L_{p}\nabla_{\mathbf{ww}}L_{p} - {(\nabla_{\mathbf{w}}L_{p})}^{2}}{L_{p}^{2}}$$

With equation (6) and (8), we may estimate the parameters with Newton\'s method.

We run the iteration until \|**w**~*new*~- **w**~*old*~\| \<*δ*, where *δ*\> 0 is a small number. In each iteration, *m*is not fixed, but updated as the number of \|*w*~*i*~\| \> *β*, where *β*is small positive number. Other algorithms such as the fixed-Hessian or conjugate gradient may also be employed to solve the above problem. The advantage of Newton\'s method is that it converges very fast when near the optimal solution. This algorithm converges from any initialization and a local maximum is guaranteed.

There is no regularization parameter tuning in this algorithm, but we have to set several approximation parameters to some reasonable values to allow the algorithm to be performed well. Theoretically, *L*~*p*~penalty gives asymptotically unbiased estimates of the nonzero parameters while shrinking the estimates of zero (or small) parameters to zero when *p*→ 0 \[[@B16]\]. Unlike LASSO (with *p*= 1) that shrinks every parameter proportionally. Therefore the lower value of p would lead to more sparse and better solutions \[[@B12]\]. However when p is very close to zero, difficulties with convergence arise. Therefore, we set *p*= 0.1 in this paper. We also set the threshold *β*= 0.001. The smoothing parameter *γ*appears in the differentiable approximation to the *L*~*p*~norm. When *γ*is too large, the approximation is not a good one and the solution is overly smooth and the sparsity property of *L*~*p*~will be lost. When *γ*is very small, the number of iterations required for convergence increases drastically. We have found empirically that a choice of *γ*which does not require very many iterations, and yet converges to very sharp solutions is around 0.001--0.0000001 for our data We therefore set *γ*= 0.000001 in all experiments.

BLpLog employs a gradient decent method with superlinear convergence. To prevent the optimization from sticking to local optimal, we randomly initialize the coefficients 20 times and choose the estimated coefficients with the best AUC value for all of the computational experiments in this paper. Our experiments, however, have shown that the computational results are not sensitive to the parameter initialization and the algorithm converges quickly to the same optimization value most of the time with different parameter initializations.

Our binary classification algorithm can be extended for multiclass classification tasks. For a general c-class problem, we can employ the standard approach where two class classifiers are trained in order to separate each of the classes against all others. The decision rules are then coupled by voting, that is, sending the sample to the class with the largest probability.

Similarity and Integrated Algorithm
-----------------------------------

In gene selection and pathway discovery, we have to deal with two important problems: (1) how to take into account the gene-gene correlations and (2) how to hunt the upstream regulatory genes. As we discussed in the previous section, current gene selection methods can only select the downstream genes with bigger changes in expression. The characteristic of the regulatory genes is that their gene expression changes may be low but they are highly correlated with the downstream highly expressed genes. We first introduce our own correlation (similarity) measure (R) for continuous variables such as gene expression data.

$$R(\mathbf{x},\mathbf{y}) = \frac{cov(\mathbf{x},\mathbf{y})}{\min\left\{ var(\mathbf{x}),var(\mathbf{y}) \right\}},$$

where $cov(\mathbf{x},\mathbf{y}) = {\sum{(\mathbf{x}_{i} - \mathbf{\overline{x}}){(\mathbf{y}_{i} - \mathbf{\overline{y}})}^{T}}}$ is the standard covariance and $var(\mathbf{x}) = {\sum{(\mathbf{x}_{i} - \mathbf{\overline{x}}){(\mathbf{x}_{i} - \mathbf{\overline{x}})}^{T}}}$ is the variance. Based on this definition we have *R*(**x**, **y**) = *R*(**y**, **x**), and *R*= 0 when **x**and **y**are independent and *R*≥ 1, when either *var*(**x**) ≤ *cov*(**x**, **y**) or *var*(**y**) ≤ *cov*(**x**, **y**). It is clear that this definition of R is different from the standard correlation coefficient $r = cov(\mathbf{x},\mathbf{y})/\sqrt{var(\mathbf{x})var(\mathbf{y})}$ in its denominator. However, R can catch the the genes that have very small changes in expression but are highly correlated with the significantly expressed (downstream) genes. For instance, given *cov*(**x**, **y**) = 0.01, *var*(**x**) = 0.01, and *var*(**y**) = 1, we have both *R*= 1 and *r*= 0.1. Our definition of R guarantees that the upstream regulatory genes and the downstream genes will be in the same group.

The Integrated Algorithm
------------------------

We now incorporate the correlation structure into the gene selection and pathway identification algorithm. Given a set of n independent observations $\left\{ \mathbf{x}_{i},y_{i} \right\}_{i = 1}^{n}$:

1\. The gene selection step: Identifying a small subset of individual genes that are associated with cancer using *L*~*p*~regularized Bayesian logistic regression

2\. For each selected gene **x**~*i*~, find all **x**~*j*~from the original data set, such that \|*R*(**x**~*i*~, **x**~*j*~)\| ≥ *h*, where *h*is a threshold and set to 0.9 for experiments in this paper.

3\. For each subset of selected genes, identify the pathways associated with it using DAVID.
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